This CIDETEC project will use bones from modified RNA and 3D printing to deal with osteoporosis. (Photo: CIDETEC)
Given the growing aging of the population, the number of diseases associated with older people is increasing. It is estimated that, worldwide, one in three women and one in five men over the age of 50 will suffer an osteoporotic bone fracture. In addition, there are other cases of deterioration of bone regeneration such as, for example, trauma with infections caused by motor vehicle accidents.
Bone is the most transplanted tissue after blood, so it is essential to have graft materials. In search of optimized regeneration solutions, the cmRNAbone project has been launched with the aim of developing a new gene therapy that improves the lives of people with major traumatic injuries or degenerative bone diseases such as osteoporosis.
The proposed approach is a unique combination of advanced genetic research, nano and biotechnology, which will be joined by 3D printing. The cmRNAbone project aims to develop chemically modified RNA that encodes specific proteins targeting neurogenesis, vasculogenesis, and osteogenesis – three main processes that influence the progression of healing. The RNA pools produced will be combined with non-viral vectors so that the RNA delivery is incorporated into a biomaterial ink formulation. CIDETEC Nanomedicine, from the Basque Country, in Spain, will develop cmRNA delivery vehicles based on optimized non-viral polysaccharides suitable for the developed matrix.
Subsequently, a 3D printer specifically designed for the implant will help demonstrate bone regeneration capabilities in practice. The new findings will be applied in two simultaneous preclinical studies in order to show the validity and clinical relevance of the therapy designed in critical size and osteoporotic bone defects.
The project, coordinated by AO Research Institute Davos in Switzerland and funded by the European Union with more than 6 million euros, is made up of 11 European partners from Austria, France, Germany, the Netherlands, Spain and Switzerland. Backed by a clinical and scientific advisory board, the SME-led consortium will ensure a quick and easy introduction to the clinic upon project completion. In the long term, the discoveries could constitute not only a regenerative approach for brittle fractures and large bone defects in the young and elderly, but also for other important diseases that affect millions of patients.
This project has been funded through the European Union’s Horizon 2020 research and innovation program under grant agreement No. 874790.
Source: CIDETEC and Amazings® / NCYT® | (Noticiasdelaciencia.com / Amazings.com)